Valued at USD 10.5 Billion in 2022, the global anaplastic large cell lymphoma (ALCL) therapeutics market is expected to develop at a CAGR of 5% over the next ten years. By the end of this forecast year in 2032, analysts anticipate the anaplastic large cell lymphoma (ALCL) therapeutics market share would be worth USD 17.1 Billion.
| Attributes | Details |
|---|---|
| Market Size Value (2022) | USD 10.5 Billion |
| Market Size Value (2032) | USD 17.1 Billion |
| Market Growth Rate (2022 to 2032) | 5% |
The growing burden of cancer patients around has surfaced as a major concern around the world. Moreover, the increasing percentage of ALCL patients is quite alarming for many nations' healthcare systems necessitating private players' assistance to curb this problem in a systemic approach. Several market players operating in the healthcare sector have recognized this as a business expansion opportunity.
The United States, with its robust healthcare infrastructure and advanced medical science, has been favorable for the establishment of many market players in the country. So, it is the leading region in terms of higher demand for anaplastic large cell lymphoma (ALCL) therapeutics as patients from all over the world reach here to avail of the service.
However, with economic development and strengthening healthcare infrastructure in Asia-Pacific countries in recent years, this region has also witnessed ample opportunities for market growth. The prevalence of the disease in the countries like China and India is expected to increase the adoption of anaplastic large cell lymphoma (ALCL) therapeutics and strengthen the foundation for new market players to compete in the global market.
As per the global anaplastic large cell lymphoma (ALCL) therapeutics market survey report, hospitals are figured out to be the dominant end-user segment in comparison to any other type of healthcare institution. However, with the establishment of a number of specialized Cancer treatment and care institutes in present years, the market share of the hospitals is anticipated to drop marginally.
Lymphoma is the most common type of blood cancer that affects that develops in the lymphatic system. Lymphoma are of two major types: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Lymphoma is caused when lymphocytes, type of white blood cells of the immune system grow and multiply uncontrollably.
Cancerous lymphocytes may travel to different parts of the body, including the spleen, blood, lymph nodes, bone marrow, and form a mass called a tumor. The two type of lymphocytes that can develop into lymphoma - B-lymphocytes (B-cells) and T-lymphocytes (T-cells).
Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma and a common subtype of T-cell lymphoma. ALCL consists of only 2% of NHLs and approx. 20% of T-cell lymphomas. ALCL symptoms includes fever, painless swelling of lymph nodes, weight loss, tiredness, backache and excessive night sweats.
It is comprised of two sub-types, based on the expression of a protein called anaplastic lymphoma kinase (ALK): ALK positive and ALK negative ALCL
According to National Cancer Institute, in the 2016, an estimated 1,685,210 new cases of cancer will be diagnosed in the United States and 595,690 people will die from the disease. NHL is the sixth most commonly diagnosed cancer in both men and women in the US.
In 2015, it is estimated that there will be 71,850 new cases of NHL (39,850 men and 32,000 women) and 19,790 deaths from NHL. According to GLOBOCAN 2012 estimates the incidence and mortality rate of NHL is 2.7% and 2.4% respectively.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
With the increasing geriatric population and rate of diagnosis will boost the overall market for ALCL therapeutics. Moreover, significant increase in the healthcare spending will boost the ALCL therapeutics market during the forecast period.
Geographically the ALCL therapeutics market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and MEA region. The areas with the highest incidence of NHL are North America, Europe, and Australasia, as well as several countries in Africa and South America. Also, more than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America; 70% of the world’s cancer deaths occur in these regions.
The ALCL can appear on body parts such as skin, organs and other part of the body, they grow slowly and are present on body for longer duration before diagnosis. ALCL that appears on skin is known as primary cutaneous ALCL.
Most common types of side effects observed are skin redness and skin irritation is caused. It is being observed that 10 percent primary cutaneous ALCL extends beyond the skin to organ or lymph. Systemic ALCL is parted depending on abnormal form of a protein on their surface called ALK or do not have abnormal form of a protein.
These are fast growing and the disease condition in ALK-positive (with abnormal protein) is different from ALK-negative (without abnormal protein). ALK-positive ALCL patients are treated with chemotherapy treatments, patients initially respond to the treatment but relapse within five years, these are found in children’s as well as adults.
ALK-negative ALCL patients are treated with stem cell transplantation after remission, these are mostly found in patients above 55 years.
Some major companies in the ALCL therapeutics market are Pfizer, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Seattle Genetics, Inc., Sareum Holdings PLC, Merck Sharp & Dohme Corp., Celgene Corporation and Valeant Pharmaceuticals North America LLC.
Principal Consultant
The global ALCL therapeutics market is segmented on the basis of route of administration, therapeutic areas and region
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market is likely to register a CAGR of 5% through 2032.
The market is currently valued at USD 10.5 Billion in 2022.
The market is likely to grow to a valuation of USD 17.1 Billion by 2032.
North America is likely to be a leading market during the forecast period.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Disease Type 6.2. Treatment Type 7. Global Market Analysis and Forecast, By Disease Type 7.1. Primary ALCL 7.2. Relapsed ALCL 8. Global Market Analysis and Forecast, By Treatment Type 8.1. Chemotherapy 8.2. (CHOP) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone 8.3. Brentuximab vedotin 8.4. Pralatrexate 8.5. Surgery 8.6. Radiation therapy 8.7. Stem cell transplant 9. Global Market Analysis and Forecast, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. Asia Pacific 9.6. East Asia 9.7. MEA 10. North America Sales Analysis and Forecast, by Key Segments and Countries 11. Latin America Sales Analysis and Forecast, by Key Segments and Countries 12. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 13. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries 14. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 15. East Asia Sales Analysis and Forecast, by Key Segments and Countries 16. MEA Sales Analysis and Forecast, by Key Segments and Countries 17. Sales Forecast by Disease Type and Treatment Type for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Takeda Pharmaceutical Company Limited 19.2. Teva Pharmaceutical Industries Ltd. 19.3. Seattle Genetics, Inc. 19.4. Sareum Holdings PLC 19.5. Merck Sharp & Dohme Corp. 19.6. Celgene Corporation 19.7. Valeant Pharmaceuticals North America LLC
Explore Healthcare Insights
View Reports
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market
